Drawing for MABLOGIX

USPTO serial 86639612

MABLOGIX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
LEE, DOUGLAS
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MABLOGIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David L. May

DAVID L. MAY Nixon Peabody Llp401 9th St NW Ste 900Washington, DC 20004-2145UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
040Custom manufacturing and custom synthesis of antibodies and genetically engineered DNA expressing antibodies, biological organisms, cells, viruses, and special purpose cells to the specifications of others for scientific, research, medical, veterinary and laboratory useACTIVE—
042Development of new technology for others in the field of medicine, genetics, therapeutics, biochemistry, and biotechnology; Development of products being antibodies and genetic therapies expressing antibodies to regulate, modulate, treat, prevent, and characterize disease states; Development of tools in the nature of biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the fields of biotechnology, genetics, and antibody technology, namely, genetically engineering DNA, biological organisms, cells, viruses, and special purpose cells expressing antibodies for scientific, research, medical, veterinary and laboratory use; Scientific research and product development services for others in the pharmaceutical, biochemical, biotechnology, veterinary, and medical fields; Antibody technology and gene therapy services for others for product development and scientific research purposes, namely, antibody production, genetically engineering DNA expressing antibodies, biological organisms, cells, viruses, and special purpose cells for scientific, research, medical, veterinary and laboratory useACTIVE—
044Medical services; Medical services, namely, antibody and gene therapy servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 18, 2016MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 18, 2016ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 15, 2015NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Oct 20, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 20, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 30, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 9, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 3, 2015DOCKASSIGNED TO EXAMINER—
May 30, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 26, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance